Search

Opportunities and pitfalls in the healthcare investment landscape: A conversation with McDermott's Brian Bunn

OPPORTUNITIES AND PITFALLS IN THE HEALTHCARE INVESTMENT LANDSCAPE: A CONVERSATION WITH MCDERMOTT'S BRIAN BUNN

Brian Bunn, a partner with international law firm McDermott Will and Emery, shared his perspective on healthcare investment in the...

Arrakis spices up development efforts with $75M Series B round for RNA-targeting drugs

ARRAKIS SPICES UP DEVELOPMENT EFFORTS WITH $75M SERIES B ROUND FOR RNA-TARGETING DRUGS

The company has raised more than $100 million since 2017 and plans to use the current funding to build a pipeline of RNA-targeting...

 
 
 
Check out the companies in Dreamit's spring 2019 HealthTech program

CHECK OUT THE COMPANIES IN DREAMIT'S SPRING 2019 HEALTHTECH PROGRAM

The seven startups are located across the United States and zero in on everything from physician notes to medical education to hand...

U.S. regulators forcing PatientsLikeMe's Chinese majority owner to sell its stake

U.S. REGULATORS FORCING PATIENTSLIKEME'S CHINESE MAJORITY OWNER TO SELL ITS STAKE

Cambridge, Massachusetts-based PatientsLikeMe is being forced to find a new buyer for the company because of the iCarbonX divesture...

 
 
 
Delivering operational command centers: improve patient access, throughput and financial stability for health systems

DELIVERING OPERATIONAL COMMAND CENTERS: IMPROVE PATIENT ACCESS, THROUGHPUT AND FINANCIAL STABILITY FOR HEALTH SYSTEMS

Operational command centers at hospitals can have positive outcomes for both patient satisfaction, patient flow and financial gains.

FERMENTATION ASSOCIATE TECHNICIAN - SD SYN BIOTECH - CARLSBAD, CA

As a member of a growing team, you are responsible for ensuring that experiments are running according to plan so attention to detail...

 
 
 
Gilead, Galapagos's filgotinib scores in Phase III rheumatoid arthritis trial, but questions remain

GILEAD, GALAPAGOS'S FILGOTINIB SCORES IN PHASE III RHEUMATOID ARTHRITIS TRIAL, BUT QUESTIONS REMAIN

Whether the FDA requires completion of a study to look at testicular toxicity before approval could dictate whether the drug launches...

Amazon is turning its controversial Rekognition software to medical image redaction

AMAZON IS TURNING ITS CONTROVERSIAL REKOGNITION SOFTWARE TO MEDICAL IMAGE REDACTION

Amazon has demonstrated the ability to combine its Comprehend Medical software service with its Rekognition image analysis to help...

 
 
 
Biogen's Alzheimer's disease drug crashes in Phase III testing

BIOGEN'S ALZHEIMER'S DISEASE DRUG CRASHES IN PHASE III TESTING

The news sent Biogen's shares down more than 26 percent pre-market, but analysts also wrote that it deals a significant blow to amyloid...

Flagship Pioneering raises $824M in new fund

FLAGSHIP PIONEERING RAISES $824M IN NEW FUND

The venture capital firm had originally set out to raise $700 million for the Special Opportunities Fund II, according to an SEC filing...

 
 
 
FDA approves Roche's Tecentriq for first-line, extensive-stage small-cell lung cancer

FDA APPROVES ROCHE'S TECENTRIQ FOR FIRST-LINE, EXTENSIVE-STAGE SMALL-CELL LUNG CANCER

The PD-L1 inhibitor is the first new drug for ES-SCLC in more than 20 years. Meanwhile, Merck is also running a Phase III study of...

Genfit, developing drugs for NASH, to trade on Nasdaq

GENFIT, DEVELOPING DRUGS FOR NASH, TO TRADE ON NASDAQ

The company, one of several developing drugs for the growing fatty liver disease, said in an SEC filing that it would sell its shares...

 
 
 
Report: College bribery scandal tip stemmed from pharma pump-and-dump investigation

REPORT: COLLEGE BRIBERY SCANDAL TIP STEMMED FROM PHARMA PUMP-AND-DUMP INVESTIGATION

The Wall Street Journal reported that Morrie Tobin tipped off investigators about the college bribery scheme, which ensnared a biotech...

NCI's Norman Sharpless named as acting FDA commissioner to succeed Gottlieb

NCI'S NORMAN SHARPLESS NAMED AS ACTING FDA COMMISSIONER TO SUCCEED GOTTLIEB

Sharpless, the director of the National Cancer Institute, was reportedly favored by HHS Secretary Alex Azar as outgoing Commissioner...

 
 
 
Roche's Tecentriq approved as first immunotherapy drug for breast cancer

ROCHE'S TECENTRIQ APPROVED AS FIRST IMMUNOTHERAPY DRUG FOR BREAST CANCER

The drug received accelerated approval for combination with Celgene's Abraxane based on Phase III data. According to a study, PD-L1-positive...

Clinical trials of Allergan's antidepressant rapastinel fail

CLINICAL TRIALS OF ALLERGAN'S ANTIDEPRESSANT RAPASTINEL FAIL

An analyst said the news could negatively affect shares of a successor to the company that developed rapastinel - which Allergan bought...

 
 
 
HBO documentary ‘The Inventor' goes inside the rise and fall of Theranos

HBO DOCUMENTARY ‘THE INVENTOR' GOES INSIDE THE RISE AND FALL OF THERANOS

Despite a couple of flaws, Alex Gibney's new film - airing March 18 - expertly portrays how Elizabeth Holmes's dream of changing the...

What's in a name? Healthcare's big potential disruptor will be called Haven

WHAT'S IN A NAME? HEALTHCARE'S BIG POTENTIAL DISRUPTOR WILL BE CALLED HAVEN

The Amazon-Berkshire-J.P. Morgan healthcare venture launched last year and headed up by Atul Gawande has a website and finally a name:...

 
 
 
Report: Purdue Pharma exploring Chapter 11 bankruptcy filing

REPORT: PURDUE PHARMA EXPLORING CHAPTER 11 BANKRUPTCY FILING

Reuters reported Monday that the maker of OxyContin was considering the filing so that it could negotiate claims with plaintiffs in...

CVS taps CIO to lead IT integration with Aetna

CVS TAPS CIO TO LEAD IT INTEGRATION WITH AETNA

Roshan Navagamuwa has been promoted to the position of executive vice president and chief information officer of CVS Health where he...